MedPath

A clinical trial to study the effects of two methods, a behavioral and drug treatment based support intervention and only brief advice for persons with severe mental illness and smoking problem

Not Applicable
Conditions
Health Condition 1: F317- Bipolar disorder, currently in remissionHealth Condition 2: F172- Nicotine dependenceHealth Condition 3: F200- Paranoid schizophreniaHealth Condition 4: F250- Schizoaffective disorder, bipolartype
Registration Number
CTRI/2019/10/021685
Lead Sponsor
Prof Pratima Murthy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Adults (>=18 years old) with SMI (i.e. schizophrenia, schizoaffective disorder, bipolar affective disorder, psychosis, severe depression with psychosis) ï?·

Considered to be stable by the mental health clinical team ï?·

Self-reported current smoker of any form of smoked tobacco product (including cigarettes, bidis, waterpipe etc) for at least 6 months ï?· Smoking on >25 days in the past month ï?·

Able to provide informed consent ï?·

Attending included institutions during the study period ï?·

Willing to cut down or quit smoking ï?·

Willing and able to attend up to 10 face-to-face counselling sessions ï?·

Living in Bangalore urban and rural districts in India

Exclusion Criteria

Pregnant or breastfeeding women ï?·

Comorbid drug and/or alcohol problems

Epilepsy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary Outcomes <br/ ><br>1.Recruitment rates 2. Reasons for ineligibility/non-participation/non-consent of participants. 3. Length of time required to achieve the required sample size. 4. Retention in study 5. Retention in treatment 6. Intervention fidelity 7. Smoking cessation pharmacotherapy adherence 8. Data completeness <br/ ><br>Timepoint: Data will be measured and collected from participants and carers at baseline, one, three and six months.
Secondary Outcome Measures
NameTimeMethod
9. Self-reported or family/carer reported continuous smoking abstinence for at least six months (only five instances of smoking allowed during the total six months) which is biochemically verified by CO concentration (CO concentration 7ppm) at six months follow-up. 10. Point abstinence, defined as a self-report or family/carer report of not smoking in the previous seven days, assessed at one, three and six months follow-up. 11. Cost of delivering the IMPACT 4S and the BA interventions.Timepoint: Data will be measured and collected from participants and carers at baseline, one, three and six months.
© Copyright 2025. All Rights Reserved by MedPath